Coagulant Therapeutics
Coagulant Therapeutics is a biotech company focused on developing therapeutics for acute bleeding, leveraging expertise in coagulation cascade and biologics. Their mission is to address unmet medical needs in bleeding disorders with innovative treatments like CT-001, a next-generation Factor VIIa, and APC-targeted antibodies. They aim to bring safe, effective, and rapid-acting solutions to treat conditions such as postpartum hemorrhage, intracranial hemorrhage, traumatic brain injury, and trauma.
Industries
Nr. of Employees
small (1-50)
Coagulant Therapeutics
2630 Bancroft Way Berkeley, CA 94704
Patents
Products
CT-001 (engineered short-acting Factor VIIa candidate)
A recombinant, engineered Factor VIIa variant designed for enhanced pro-hemostatic potency at sites of bleeding combined with rapid systemic clearance to reduce thrombogenic risk.
APC-targeted antibody candidates (nanobody-derived leads, e.g., CT-003 / CT-005)
Antibody and nanobody-derived therapeutic candidates directed to activated protein C (APC) designed to selectively modulate anticoagulant, anti-inflammatory and cytoprotective activities for indications including trauma, hemophilia and sepsis.
CT-001 (engineered short-acting Factor VIIa candidate)
A recombinant, engineered Factor VIIa variant designed for enhanced pro-hemostatic potency at sites of bleeding combined with rapid systemic clearance to reduce thrombogenic risk.
APC-targeted antibody candidates (nanobody-derived leads, e.g., CT-003 / CT-005)
Antibody and nanobody-derived therapeutic candidates directed to activated protein C (APC) designed to selectively modulate anticoagulant, anti-inflammatory and cytoprotective activities for indications including trauma, hemophilia and sepsis.
Services
Collaborative research agreements and joint development opportunities focused on coagulation-targeted biologics, including access to discovery libraries, assay platforms and preclinical models.
Collaborative research agreements and joint development opportunities focused on coagulation-targeted biologics, including access to discovery libraries, assay platforms and preclinical models.
Expertise Areas
- Biologics discovery and development
- Protein engineering and glycoengineering
- Antibody (nanobody) discovery and optimization
- Coagulation biology and hemostasis
Key Technologies
- Nanobody libraries (llama-derived single-domain antibodies)
- Directed evolution for antibody optimization
- Protein engineering of coagulation factors
- Glycoengineering/desialylation for PK control
News & Updates
The company sponsored study explores APC-targeted antibodies that selectively modulate anticoagulant and anti-inflammatory activities, offering potential therapeutic solutions for conditions like traumatic bleeding, hemophilia, sepsis, and ischemia.
The study demonstrates the enhanced activity of CT-001, a novel fast-clearing Factor VIIa, in postpartum blood samples, supporting its development for severe postpartum hemorrhage.
The company sponsored study explores APC-targeted antibodies that selectively modulate anticoagulant and anti-inflammatory activities, offering potential therapeutic solutions for conditions like traumatic bleeding, hemophilia, sepsis, and ischemia.
The study demonstrates the enhanced activity of CT-001, a novel fast-clearing Factor VIIa, in postpartum blood samples, supporting its development for severe postpartum hemorrhage.